PPT-Switch to DTG/ABC/3TC

STRIIVING Study Design Endpoints Primary proportion of patients maintaining HIV RNA lt 50 cmL at W48 ITTE snapshot noninferiority if lower margin of the twosided 95 CI for the difference 10 90 power . 9 FM 955 FM 939 FM 931 FM Almaden 64 1065 FM 1045 FM Alpha 1057 FM 1073 FM Aramac 1079 FM Atherton 67 720 AM Augathella 11 9a 1077 FM Aurukun 1029 FM Ayr 62 Ayton 62 1039 FM 1071 FM Babinda 42 957 FM 941 FM Ballera 56 1059 FM 1043 FM 1027 FM Bancroft FLAMINGO. GS-236-0103. ACTG A5257. WAVES. ARIA . Design. Objective. Non inferiority of DTG/ABC/3TC at W48: % HIV RNA < 50 c/mL by intention. to treat, snapshot analysis (lower margin of the 2-sided 95% CI for the difference = - 12%). 2. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; . 3. Hospital La Paz, Madrid, Spain; . 4. Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, . ATV/r 300/100 mg QD 3TC 300 mg QD. N = 133. N = 133. Continuación ATV/r 300/100 mg QD 2 NRTI . Diseño. Randomización. 1:1. Etiqueta abierta. Objetivo. Endpoint. primario: proporción de pacientes sin fallo al tratamiento a S48 . STARTMRK. GS-US-236-0102 . SINGLE. Walmsley. S. NEJM 2013;369:1807-18. Design. Objective. Non inferiority of DTG at W48: % HIV RNA < 50 c/mL by intention to treat, snapshot analysis (1-sided significance level of 2.5%, lower margin of . Geneva, March 19 - 20 , 2015 1 | Treatment and Care Team Meg Doherty, Marco Vitoria, Martina Penazzato, Nathan Ford Update on CADO/PADO: what are the challenges in using the current guidelines an nd. 90: Child Friendly Formulations . Victor Musiime, . MBChB. , MMED, PhD. Senior Lecturer, . Makerere. University. Investigator, Joint Clinical Research Centre. Kampala, Uganda. Disclosure statement. Dolutegravir based regimens in first- ad second-line HIV Treatment. Meg . Doherty,. MD, PhD, MPH. WHO Geneva. Sunday 21 July, 2019. Increase in people receiving ART over time . (62% ART coverage). Source: UNAIDS/WHO . Endpoints. Primary: proportion of patients with HIV RNA ≥ 50 c/mL at W48 (ITT-E, snapshot) ; non-inferiority if upper margin of the two-sided 95% CI for the difference = 4%, 97.3% power . Secondary: proportion of patients with HIV RNA < 50 c/mL at W48 (ITT-E, snapshot) ; non-inferiority if lower margin of the two-sided 95% CI for the difference = - 8%. by Baseline NRTI Resistance . and Second-Line NRTI Use. Dannae. Brown,. 1. . Ruolan. Wang,. 2. Mark Underwood,. 2. Judy Hopking,. 3. Maria Claudia Nascimento,. 4. . Michael Aboud,. 4. . Jörg. 1. ViiV Healthcare, Brentford, UK; . 2. Centre Hospitalier de Tourcoing, Tourcoing, France; . 3. Holdsworth House Medical Brisbane, Queensland, Australia; . 4. CHU Saint-Pierre, Brussels, Belgium; . 5. ADVANCE. . Design. Primary endpoint. Proportion of patients with HIV RNA < 50 c/mL at W48, ITT-E snapshot analysis ; non-inferiority of TFA/FTC if lower margin CI for . the difference = - 10%, 80% power. Andrew Hill, Francois Venter, Eric . Delaporte. , . Simiso. Sokhela, Charles . Kouanfack. , . Michelle Moorhouse. , Kaitlyn McCann, Bryony Simmons. , . Alexandra . Calmy. Disclosures. Speaker fees and honoraria from Gilead Sciences, AbbVie, Cipla, Johnson and Johnson, Sanofi, Pfizer, ViiV Healthcare, Mylan and Southern African HIV Clinicians Society. ROCKET-1 Trial. Switch from EFV + ABC-3TC to EFV-TDF-FTC. ROCKET-1: Design. Source: Moyle GJ, et al. . PLoS. One. 2015;10:e0116297.. Immediate switch arm. EFV-TDF-FTC. . (n = 79). Delayed switch arm .